Table 2. Summary of key outcome data over 16 week period of study.
| Study A | Study B | |||
|---|---|---|---|---|
| n | 336 | 59 | ||
| Bother score (0–10) | Mean (SD) | 4.45 (2.35) | 3.46 (2.70) | |
| Median (IQR) | 4.48 (3.26, 5.83) | 3 (1, 5) | ||
| Days in flare | Escalation of treatment(0–112 days) | Mean (SD) | 23.26 (25.06) | 22.64 (19.54) |
| Median (IQR) | 15 (3,37) | 18 (8.50, 30.50) | ||
| Anti-inflammatory medication used(0–112 days) | Mean (SD) | 49.60 (36.00) | N/A | |
| Median (IQR) | 43.50 (19,73.75) | N/A | ||
| POEM (0–28 points) | Mean (SD) | 12.52 (6.70) | 10.08 (6.31) | |
| TIS (0–9 points) | Mean (SD) | 2.67 (1.82) | 2.38 (1.68) | |
| SASSAD (0–108 points) | Mean (SD) | 20.31 (13.14) | N/A | |
Abbreviations: Patient Oriented Eczema Measure (POEM), Six area, six sign atopic dermatitis (SASSAD), Not applicable (N/A), Three item severity score (TIS).